Submitted and Pending Review

Submitted Grants as PI since February 2021

  1. NIH/NIDDK: R01DK144073-01 – $2,495,198
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Metabolic MRI of Oxygen Metabolism in Visceral Adipose Tissue with High Salt Intake Intervention
    Status: Pending IRG Review
  2. NIH/NCI: R01CA303247-01 – $2,500,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    MRI Monitoring Clinically Bacteriolytic Transarterial Embolization for Cancer Therapy
    Status: Pending IRG Review
  3. NIH/NCI: R01CA291927-01A1 – $2,500,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    MRI-guided Irreversible Electroporation Combined with Engineered NK Cell Immunotherapy for Liver Tumors
    Status: Pending IRG Review
  4. NIH/NCI: R01CA241532 – $2,434,292
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Image-Guided Combination Immunoelectroporation to Boost Therapeutic Response for Liver Cancer
    Status: Pending IRG Review
  5. NIDDK/NCI: R01CA291910-01A1 – $2,446,187
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Emerging MRI Techniques for Monitoring Cachexia Progression and Treatment
    Status: Pending IRG Review
  6. NIH: S10OD036426-01A1 – $2,000,000
    PI: Zhuoli Zhang
    High-Field 7T MRI System to Accelerate Translational Sciences
    Status: Pending IRG Review, Initial Scored: Impact score 48
  7. NIH/NCI: R01DK141464 – $2,152,633
    PIs: Zhuoli Zhang and Vahid Yaghmai
    ZS-MRI Approach to Explore the Impact of High Sodium Intake on VAT
    Status: Pending IRG Review
  8. NIH/NCI: R01CA295523 – $431,750
    PIs: Zhuoli Zhang and Vahid Yaghmai
    TRIP-MRI-Guided Intrahepatic Artery-Delivered ICI and TKI Nanospheres Combination Therapy for HCC
    Status: Pending IRG Review
  9. NIH/NCI: R21CA295472 – $2,152,633
    PI: Zhuoli Zhang
    Developing Translational CMR Imaging Protocol for Early Detection of ICI-Associated Myocarditis
    Status: Pending IRG Review
  10. NIH/NCI: R01CA291941 – $2,873,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Advancing Microbial-based Imaging for Cancer Therapy
    Status: Not Discussed
  11. NIH/NCI: R01CA291927 – $2,873,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    MRI-Guided Irreversible Electroporation Combined with Engineered NK Cell Immunotherapy for Liver Tumors
    Status: Impact Score 46 and Percentile 35
  12. NIH/NCI: R01CA291941 – $2,873,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Emerging MRI Techniques for Monitoring Cachexia Progression and Treatment
    Status: Impact Score 46 and Percentile 38
  13. NIH/NCI: R21CA289106 – $495,000
    PI: Zhuoli Zhang
    Developing a Translational CMR Imaging Framework for Early Detection of Drug-Induced Myocarditis
    Status: Not Discussed
  14. NIH: S10OD036426 – $2,000,000
    PI: Zhuoli Zhang
    High-Field 7T MRI System to Accelerate Translational Sciences
    Status: Impact Score 48
  15. NIH/NCI: R01CA288514 – $2,476,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Developing Novel MRI Approaches to Guide Irreversible Electroporation Ablation for a Combination Therapy for PDAC using Mouse Models
    Status: Percentile 44 and IS 54
  16. NIH/NCI: R01CA288649 – $2,381,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Development of AI-Derived MRI Approaches for Cancer Therapy
    Status: Not Discussed
  17. NIH/NCI: R01CA290031 – $2,463,000
    PIs: Liangzhong Xiang and Zhuoli Zhang
    EAT/US-Guided Irreversible Electroporation Ablation for Liver Tumors
    Status: Pending IRG Review
  18. NIH/NIBIB: 1R01CA287470-01 – $2,500,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Wensha Yang (UCFS)
    MRI Monitoring of Electroporation Enhances NK Adoptive Transfer Immunotherapy Against HCC
    Status: Not Discussed
  19. NIH/NIBIB: R01EB035099 – $2,475,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Kejia Cai (UIC subcontract)
    Z-Spectrum MRI Technique to Measure Function and Volume of Brown Adipose Tissue as Biomarkers in a Mouse Model
    Status: Pending IRG Review
  20. NIH/NCI: R01CA285553 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Combination of NK-Based Adoptive Transfer Immunotherapy and Molecular Targeted Therapy Against HCC
    Status: Pending IRG Review
  21. NIH/NCI: R01CA285483 – $2,475,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Advancing Clostridium novyi-NT therapy against solid tumors
    Status: Pending IRG Review
  22. NIH/NCI: R01CA285449 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    MRI-guided immune checkpoint plus molecular targeted inhibitors against liver cancer in animal models
    Status: Pending IRG Review
  23. NIH/NCI: R01CA209886 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Developing MRI-Guided Preventive Dendritic Cell Vaccination Strategy to Avoid Post-surgical Pancreatic Cancer Recurrence and Metastasis
    Status: A resubmission of renewal (Original submission IF: 47 with 32%, resubmission reviewed on 2/23/2023 IF: 30 with 9%, waiting for NIH notice of Award)
  24. NIH/NCI: R01CA282146 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Combination immunotherapy of an immune checkpoint inhibitor and tumor vaccine for pancreatic cancer with MRI monitoring
    Status: Not discussed
  25. NIH/NCI: R01CA282145 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Overcoming immunosuppressive tumor microenvironment to enhance dendritic cell-based immunotherapy for pancreatic cancer using multiparametric MRI monitoring
    Status: Not discussed
  26. NIH/NIDDK: R01DK136559 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Longitudinal assessment of visceral adipose tissue hypoxia induced by high sodium intake using MRI
    Status: Not discussed
  27. NIH/NIDDK: R01DK133313 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Development of novel metabolic MRI technique to measure the function of Brown Adipose Tissue for Metabolic Diseases
    Status: Resubmission IF:33 with 18%. (First submission IF: 37 with 25%)
  28. NIH/NCI: R01CA278771 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Image-guided Clostridium novyi-NT immunotherapy for advanced solid tumors
    Status: Not discussed (First submission)
  29. NIH/NCI: R01CA279235 – $1,975,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Nadine Abi-Jaoudeh
    Developing and validating new MRI biomarkers for dynamic monitoring of tumor response to locoregional immunotherapy for liver tumor
    Status: Not discussed (First submission)
  30. NIH/NCI: R01CA278602 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Develop a clinically applicable MRI-guided nanosphere delivery platform for combination immunotherapy-molecular targeted therapy in hepatocellular carcinoma
    Status: Not discussed (First submission)
  31. NIH/NIDDK: R01DK132767 – $1,975,000
    PIs: Zhuoli Zhang and Kejia Cai (UIC subcontract)
    Develop a novel Z-Spectrum MRI technique for noninvasively longitudinal monitoring of the hypoxia, edema, and metabolic stress of visceral adipose tissues
    Status: Not discussed (First submission)
  32. NIH/NIDDK: R01DK132767 – $1,975,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Kejia Cai (UIC subcontract)
    Develop a novel Z-Spectrum MRI technique for noninvasively longitudinal monitoring of the hypoxia, edema, and metabolic stress of visceral adipose tissues
    Status: Not discussed (Resubmission)
  33. NIH/NCI: R01CA276688 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Novel imaging approaches monitoring irreversible electroporation boosting dendritic cell anti-cancer immune response for pancreatic cancer
    Status: Not discussed
  34. NIH/NCI: R01CA269641 – $1,975,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Min-Ying L Su
    Developing Combinatorial Immunotherapy and Response Monitoring Models with Imaging and Immuno-biomarkers for PDAC
    Status: Not discussed (First submission)
  35. NIH/NCI: R01CA269641 – $1,975,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Min-Ying L Su
    Developing Combinatorial Immunotherapy and Response Monitoring Models with Imaging and Immuno-biomarkers for PDAC
    Status: Not discussed (Resubmission)
  36. NIH/NCI: R01CA273144 – $1,975,000
    PI: Zhuoli Zhang
    Development of a novel Clostridium novyi-NT therapeutic strategy for advanced solid tumors
    Status: Not discussed
  37. NIH/NCI: R01CA209886 – $1,962,500
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Developing MRI-Guided Preventive Dendritic Cell Vaccination Strategy to Avoid Post-surgical Pancreatic Cancer Recurrence and Metastasis
    Status: Renewal-first submission (IF: 47 with 32%)
  38. NIH/NCI: R01CA269346 – $1,975,000
    PIs: Zhuoli Zhang, Vahid Yaghmai, and Nadine Abi-Jaoudeh
    Developing MR Imaging Biomarkers for Dynamic Evaluation of the Combination of IRE and immunotherapy to improve the therapeutic response
    Status: Not discussed
  39. NIH/NIDDK: R01DK131212 – $1,975,000
    PIs: Zhuoli Zhang and Kejia Cai (UIC subcontract)
    Development of ZS-MR Imaging Metabolic Signatures of Brown Adipose Tissue as Biomarkers for Metabolic Diseases
    Status: Not discussed
  40. NIH/NCI: R01CA244338 – $1,962,500
    PIs: Vahid Yaghmai and Zhuoli Zhang
    MRI-monitoring of DC vaccine therapy in the prevention of PDAC recurrence after surgical resection
    Status: Resubmission (IF: 50 with 38%)
  41. NIH/NCI: R01CA263529 – $1,975,000
    PI: Zhuoli Zhang
    MRI monitoring of combination irreversible electroporation with dendritic cell-based vaccination for pancreatic cancer
    Status: Not discussed
  42. NIH/NCI: R01CA263529 – $1,975,000
    PI: Zhuoli Zhang
    Electroporation-mediated contrast agent transfection (ECAT)-MRI for evaluation of IRE ablation for pancreatic cancer
    Status: Not discussed
  43. NIH/NCI: R01CA262738 – $1,975,000
    PI: Zhuoli Zhang
    Developing novel AI-derived MR imaging biomarkers for evaluation of cancer immunotherapy
    Status: Not discussed
  44. NIH/NIDDK: R01DK125373 – $1,975,000
    PIs: Zhuoli Zhang and Kejia Cai (UIC subcontract)
    Development and Application of ZS-MR Imaging Metabolic Signatures of Brown Adipose Tissue As Biomarkers for Cachexia Therapy
    Status: First submission (IF: 44 with 29%)
  45. NIH/NIDDK: R01DK125373 – $1,975,000
    PIs: Zhuoli Zhang and Kejia Cai (UIC subcontract)
    Development and Application of ZS-MR Imaging Metabolic Signatures of Brown Adipose Tissue As Biomarkers for Cachexia Therapy
    Status: Resubmission (IF: 40 with 23%)
  46. NIH/NCI: R01CA273017 – $1,975,000
    PIs: Zhuoli Zhang and Vahid Yaghmai
    Developing Artificial Intelligence-Derived MR Imaging Biomarkers for Assessment of Tumor Microenvironment
    Status: Not discussed